ClinicalTrials.Veeva

Find clinical trials for Acute Myeloid Leukemia (AML) in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Leukemia
Acute Myeloid Leukemia
Myeloid Leukemia
Myelodysplastic Syndromes
Preleukemia
Syndrome
Cancer

Acute Myeloid Leukemia (AML) trials near Valencia, VC, ESP:

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: LoDAC (Low Dose Cytarabine)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)

Phase 3

Astellas
Astellas

Valencia, Spain and 125 other locations

The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Other: Best Supportive Care (BSC)
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Madrid, Spain and 164 other locations

Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute...

Enrolling
Relapsed or Refractory Acute Myeloid Leukemia
Drug: Tuspetinib
Drug: Venetoclax Oral Tablet

Phase 1, Phase 2

Aptose Biosciences

Valencia, Spain and 33 other locations

two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: GSK3745417

Phase 1

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Valencia, Spain and 10 other locations

when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Valencia, Valenciana, Spain and 108 other locations

[GO]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who...

Enrolling
Acute Myeloid Leukemia
Drug: Fludarabine
Drug: Cytarabine

Phase 3

LLS PedAL Initiative, LLC

València, Spain and 71 other locations

This is a clinical study for adult patients who have recently been diagnosed with acute myeloid leukemia or AML. ...

Active, not recruiting
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Acute Myeloid Leukemia (AML)
Drug: gilteritinib
Drug: azacitidine

Phase 3

Astellas
Astellas

Valencia, Spain and 110 other locations

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid...

Active, not recruiting
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: CC-90009

Phase 1

Celgene
Celgene

Valencia, Spain and 18 other locations

This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) ...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Placebo
Drug: Oral Azacitidine

Phase 3

Celgene
Celgene

Valencia, Spain and 222 other locations

combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated acute...

Active, not recruiting
Refractory Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Drug: Lanraplenib
Drug: Gilteritinib

Phase 1, Phase 2

Kronos Bio

Valencia, Spain and 16 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems